rare cancer

Oncology

pharmaphorum podcast Episode 265, Leonard Mazur, Citius

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.

Oncology

ESMO25: The changing landscape of rare oncology, with Jan Ki...

ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.

Oncology

Addressing the oncological ‘other’: How predictive analysis ...

In a new report, ‘Helping others: unlocking the potential of

Oncology

Understanding and addressing care disparities in rare cancer...

Any cancer diagnosis is scary and signals a long, challenging road ahead.

News

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejec...

News

Daiichi gets speedy FDA review for rare cancer drug

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT).

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

ESMO25: The changing landscape of rare oncology, with Jan Ki...

Addressing the oncological ‘other’: How predictive analysis ...

Understanding and addressing care disparities in rare cancer...

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejec...

Daiichi gets speedy FDA review for rare cancer drug

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

rare cancer

Editor's Picks